Tayebinia Minoosadat, Sharifzadeh Sedigheh, Rafiei Dehbidi Gholamreza, Zare Farahnaz, Ranjbaran Reza, Rahimi Amir, Miri Mohammad Reza, Mirzakhani Mehdi, Behzad-Behbahania Abbas
Diagnostic Laboratory Sciences and Technology Research Center, School of Paramedical Sciences, Shiraz University of Medical Sciences, Shiraz, Iran.
Division of Medical Biotechnology, Department of Medical Laboratory Sciences, School of Paramedical Sciences, Shiraz University of Medical Sciences, Shiraz, Iran.
Avicenna J Med Biotechnol. 2023 Jul-Sep;15(3):173-179. doi: 10.18502/ajmb.v15i3.12927.
Antigen presentation using bacterial surface display systems, on one hand, has the benefits of bacterial carriers, including low-cost production and ease of manipulation. On the other hand, the bacteria can help in stimulating the immune system as an adjuvant. For example, using bacterial surface display technology, we developed a hepatitis C virus (HCV) multiple antigens displaying bacteria's surface and then turned it into a bacterial ghost.
The HCV core and NS3 proteins' conserved epitopes were cloned into the gene plasmid as an auto transporter. The recombinant plasmid was then transformed into () Bl21 (DE3). Recombinant bacteria were then turned into a bacterial ghost, an empty cell envelope. Whole-cell ELISA, flow cytometry, and Western blot techniques were used for monitoring the expression of proteins on the surface of bacteria.
A fusion protein of HCV core-NS3-AIDA was successfully expressed on the Bl21 (DE3) surface and confirmed by western blotting, Enzyme-Linked Immunosorbent Assay (ELISA), and flow cytometry detection techniques.
The presence of HCV antigens on non-pathogen bacteria surfaces holds promise for developing safe and cost-benefit-accessible vaccines with optimal intrinsic adjuvant effects and exposure of heterologous antigens to the immune system.
使用细菌表面展示系统进行抗原呈递,一方面具有细菌载体的优势,包括低成本生产和易于操作。另一方面,细菌可作为佐剂帮助刺激免疫系统。例如,利用细菌表面展示技术,我们开发了一种在细菌表面展示丙型肝炎病毒(HCV)多种抗原的细菌,然后将其制成细菌幽灵。
将HCV核心蛋白和NS3蛋白的保守表位作为自转运蛋白克隆到基因质粒中。然后将重组质粒转化到()Bl21(DE3)中。随后将重组细菌制成细菌幽灵,即空的细胞包膜。采用全细胞酶联免疫吸附测定(ELISA)、流式细胞术和蛋白质印迹技术监测细菌表面蛋白的表达。
HCV核心-NS3-AIDA融合蛋白在Bl21(DE3)表面成功表达,并通过蛋白质印迹、酶联免疫吸附测定(ELISA)和流式细胞术检测技术得到证实。
非致病细菌表面存在HCV抗原,有望开发出具有最佳内在佐剂效应且能使异源抗原暴露于免疫系统的安全、成本效益高且易于获取的疫苗。